Trial Profile
Therapeutic Efficacy of Wilms' Tumor Gene (WT1) mRNA-electroporated Autologous Dendritic Cell Vaccination in Patients With Solid Tumors: a Phase I/Feasibility Study
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Mar 2023
Price :
$35
*
At a glance
- Drugs Cancer vaccine (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Glioblastoma; Malignant-mesothelioma; Sarcoma; Solid tumours
- Focus Pharmacodynamics
- 02 Mar 2023 Status changed from recruiting to completed.
- 11 Jul 2013 Planned End Date changed from 1 Feb 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
- 15 Feb 2011 New trial record